Extraintestinal Hodgkinʼs Disease in a Patient with Crohnʼs Disease

Calvo-Villas, José Manuel; Sánchez, María José Ramirez; Tovar, Jorge Cuesta; García, Carlos Fernández

doi:10.1097/01.smj.0000074507.31006.79

Cited by 11 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final study in Crohn's disease specifically reported that there were no adverse events [10]. Of the 6 studies in ulcerative colitis, 3 studies did not report if there were any adverse events [12,51,53] while 3 studies specifically reported that there were no adverse events [50,52,54]. …”

Section: Resultsmentioning

confidence: 99%

Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis

Rossignol¹

2012

Med Gas Res

View full text Add to dashboard Cite

BackgroundTraditionally, hyperbaric oxygen treatment (HBOT) has been used to treat a limited repertoire of disease, including decompression sickness and healing of problem wounds. However, some investigators have used HBOT to treat inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.MethodsComprehensive searches were conducted in 8 scientific databases through 2011 to identify publications using HBOT in IBD. Human studies and animal models were collated separately.ResultsThirteen studies of HBOT in Crohn's disease and 6 studies in ulcerative colitis were identified. In all studies, participants had severe disease refractory to standard medical treatments, including corticosteroids, immunomodulators and anti-inflammatory medications. In patients with Crohn's disease, 31/40 (78%) had clinical improvements with HBOT, while all 39 patients with ulcerative colitis improved. One study in Crohn's disease reported a significant decrease in proinflammatory cytokines (IL-1, IL-6 and TNF-alpha) and one study in ulcerative colitis reported a decrease in IL-6 with HBOT. Adverse events were minimal. Twelve publications reported using HBOT in animal models of experimentally-induced IBD, including several studies reporting decreased markers of inflammation or immune dysregulation, including TNF-alpha (3 studies), IL-1beta (2 studies), neopterin (1 study) and myeloperoxidase activity (5 studies). HBOT also decreased oxidative stress markers including malondialdehyde (3 studies) and plasma carbonyl content (2 studies), except for one study that reported increased plasma carbonyl content. Several studies reported HBOT lowered nitric oxide (3 studies) and nitric oxide synthase (3 studies) and one study reported a decrease in prostaglandin E2 levels. Four animal studies reported decreased edema or colonic tissue weight with HBOT, and 8 studies reported microscopic improvements on histopathological examination. Although most publications reported improvements with HBOT, some studies suffered from limitations, including possible publication and referral biases, the lack of a control group, the retrospective nature and a small number of participants.ConclusionsHBOT lowered markers of inflammation and oxidative stress and ameliorated IBD in both human and animal studies. Most treated patients were refractory to standard medical treatments. Additional studies are warranted to investigate the effects of HBOT on biomarkers of oxidative stress and inflammation as well as clinical outcomes in individuals with IBD.

show abstract

Section: Resultsmentioning

confidence: 99%

Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis

Rossignol¹

2012

Med Gas Res

View full text Add to dashboard Cite

show abstract

“…HBO is used as an adjuvant therapy for various inflammatory diseases [31][32][33][34][35]. Many studies have been performed to investigate the effect of HBO treatment in experimental colitis and clinical IBD [36][37][38][39]. It has been reported that after 7 days therapy with HBO mucosal NOS activity was diminished, and this finding was attributed to the anti-inflammatory effect of HBO in experimental colitis [12].…”

Section: Discussionmentioning

confidence: 99%

The Effect of iNOS Inhibitors and Hyperbaric Oxygen Treatment in a Rat Model of Experimental Colitis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The most common subtypes are diffuse large B cell lymphoma, follicular lymphoma and Hodgkin lymphoma[1]. Cases of primary intestinal HL in CD patients are commonly reported[5], but only a few isolated cases of HL in CD patients have been described in extra-intestinal sites, such as the cervical and supraclavicular lymph nodes[2,3]. …”

Section: Discussionmentioning

confidence: 99%

“…Interestingly, patients with a history of inflammatory bowel disease (IBD) who are treated with immunosuppressants have been noted to have an increased risk of lymphoma; most cases that have been identified in this setting involve non-Hodgkin lymphoma (NHL). There have been few reported cases of primary intestinal HL in Crohn’s disease (CD) patients[1], and the development of extraintestinal HL in patients with CD has been reported even less frequently[2,3]. Herein, we describe a case of CD and small bowel obstruction complicated by the development of pulmonary HL in a 27-year-old man.…”

mentioning

confidence: 99%